vs
Apellis Pharmaceuticals, Inc.（APLS）与MYRIAD GENETICS INC（MYGN）财务数据对比。点击上方公司名可切换其他公司
MYRIAD GENETICS INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$209.8M vs $199.9M），MYRIAD GENETICS INC同比增速更快（-0.4% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
麦利亚德基因公司是总部位于美国犹他州盐湖城的美国基因检测与精准医疗企业。公司拥有多项自主专利技术，帮助医生与患者了解人类疾病的遗传基础，以及基因在疾病发生、发展和治疗中发挥的作用，相关成果可用于开发评估患病风险、指导疾病诊疗的新产品。
APLS vs MYGN — 直观对比
营收规模更大
MYGN
是对方的1.0倍
$199.9M
营收增速更快
MYGN
高出5.6%
-5.9%
两年增速更快
APLS
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $209.8M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 70.0% |
| 营业利润率 | -25.6% | -2.7% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -0.4% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSMYGN
| Q4 25 | $199.9M | $209.8M | ||
| Q3 25 | $458.6M | $205.7M | ||
| Q2 25 | $178.5M | $213.1M | ||
| Q1 25 | $166.8M | $195.9M | ||
| Q4 24 | $212.5M | $210.6M | ||
| Q3 24 | $196.8M | $213.3M | ||
| Q2 24 | $199.7M | $211.5M | ||
| Q1 24 | $172.3M | $202.2M |
净利润APLSMYGN
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-27.4M | ||
| Q2 25 | $-42.2M | $-330.5M | ||
| Q1 25 | $-92.2M | $-100.0K | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-22.1M | ||
| Q2 24 | $-37.7M | $-36.7M | ||
| Q1 24 | $-66.4M | $-26.0M |
毛利率APLSMYGN
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 68.5% | ||
| Q4 24 | — | 71.7% | ||
| Q3 24 | — | 70.2% | ||
| Q2 24 | — | 69.6% | ||
| Q1 24 | — | 68.1% |
营业利润率APLSMYGN
| Q4 25 | -25.6% | -2.7% | ||
| Q3 25 | 48.7% | -11.3% | ||
| Q2 25 | -18.6% | -154.5% | ||
| Q1 25 | -50.0% | -14.8% | ||
| Q4 24 | -12.3% | -18.6% | ||
| Q3 24 | -24.0% | -9.4% | ||
| Q2 24 | -14.7% | -17.3% | ||
| Q1 24 | -36.0% | -13.8% |
净利率APLSMYGN
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -13.3% | ||
| Q2 25 | -23.6% | -155.1% | ||
| Q1 25 | -55.3% | -0.1% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -10.4% | ||
| Q2 24 | -18.9% | -17.4% | ||
| Q1 24 | -38.5% | -12.9% |
每股收益（稀释后）APLSMYGN
| Q4 25 | $-0.40 | $-0.09 | ||
| Q3 25 | $1.67 | $-0.29 | ||
| Q2 25 | $-0.33 | $-3.57 | ||
| Q1 25 | $-0.74 | $0.00 | ||
| Q4 24 | $-0.30 | $-0.47 | ||
| Q3 24 | $-0.46 | $-0.24 | ||
| Q2 24 | $-0.30 | $-0.41 | ||
| Q1 24 | $-0.54 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $149.6M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $370.1M | $368.0M |
| 总资产 | $1.1B | $706.6M |
| 负债/权益比越低杠杆越低 | — | 0.33× |
8季度趋势，按日历期对齐
现金及短期投资APLSMYGN
| Q4 25 | $466.2M | $149.6M | ||
| Q3 25 | $479.2M | $145.4M | ||
| Q2 25 | $370.0M | $74.4M | ||
| Q1 25 | $358.4M | $91.8M | ||
| Q4 24 | $411.3M | $102.4M | ||
| Q3 24 | $396.9M | $99.9M | ||
| Q2 24 | $360.1M | $97.3M | ||
| Q1 24 | $325.9M | $104.3M |
总债务APLSMYGN
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSMYGN
| Q4 25 | $370.1M | $368.0M | ||
| Q3 25 | $401.2M | $372.8M | ||
| Q2 25 | $156.3M | $388.1M | ||
| Q1 25 | $164.2M | $704.9M | ||
| Q4 24 | $228.5M | $701.1M | ||
| Q3 24 | $237.1M | $731.7M | ||
| Q2 24 | $264.3M | $740.5M | ||
| Q1 24 | $266.7M | $760.0M |
总资产APLSMYGN
| Q4 25 | $1.1B | $706.6M | ||
| Q3 25 | $1.1B | $728.1M | ||
| Q2 25 | $821.4M | $677.3M | ||
| Q1 25 | $807.3M | $1.0B | ||
| Q4 24 | $885.1M | $1.0B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.1B |
负债/权益比APLSMYGN
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $10.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSMYGN
| Q4 25 | $-14.2M | $10.6M | ||
| Q3 25 | $108.5M | $21.1M | ||
| Q2 25 | $4.4M | $-13.6M | ||
| Q1 25 | $-53.4M | $-16.3M | ||
| Q4 24 | $19.4M | $6.6M | ||
| Q3 24 | $34.1M | $700.0K | ||
| Q2 24 | $-8.3M | $2.6M | ||
| Q1 24 | $-133.0M | $-18.6M |
自由现金流APLSMYGN
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSMYGN
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSMYGN
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSMYGN
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
MYGN
暂无分部数据
